Regulatory Guide
503A vs 503B Compounding: What Clinics Need to Know
Understanding the regulatory difference between 503A compounding pharmacies and 503B outsourcing facilities is essential for any clinic sourcing compounded peptides, biologics, or regenerative compounds. This guide explains both pathways, what documentation to require, and how to choose the right sourcing model for your practice.
Written by Benn Bluestein-Veyra, M.Sc. Organic Chemistry — Founder, ExaVeyra Sciences
The ExaBlog
Want the full narrative — including the GLP-1 shortage story and the February 2025 regulatory shift?
What Is Pharmaceutical Compounding?
Pharmaceutical compounding is the process of creating a customized medication for a specific patient or clinical need — combining, mixing, or altering ingredients to meet requirements that commercially available, FDA-approved drugs cannot address. Compounding has been practiced by pharmacists for centuries and remains a critical tool in modern clinical medicine.
For regenerative medicine practices, compounding is the primary legal pathway for accessing bioactive peptides, growth factors, and other small molecules that are not available as FDA-approved commercial products. The Drug Quality and Security Act (DQSA) of 2013 formalized two distinct regulatory frameworks for compounding — Section 503A and Section 503B — each governing a different type of compounding operation with different compliance requirements and clinical applications.
Understanding which framework governs your supplier, and what documentation obligations flow from each, is essential for any clinic building a compliant regenerative medicine practice.
503A Compounding Pharmacies
Section 503A of the Federal Food, Drug, and Cosmetic Act governs traditional compounding pharmacies. A 503A pharmacy prepares compounded medications for individual patients based on valid prescriptions from licensed practitioners. The patient-prescription relationship is central to 503A — each compounded preparation must be tied to a specific patient's documented medical need.
503A pharmacies operate primarily under state pharmacy board oversight, though they must comply with applicable federal law including using FDA-approved bulk drug substances. They follow USP standards — most importantly USP 797 for sterile compounding, USP 795 for non-sterile compounding, and USP 800 for hazardous drug handling. They are not required to register with the FDA and are generally inspected by state pharmacy boards rather than federal inspectors.
For clinics, the key practical constraint of 503A is that you cannot maintain clinic inventory of 503A compounded products without patient-specific prescriptions. Each order must correspond to an identified patient with a valid prescription. Interstate distribution is generally limited, though specific exemptions apply.
503A — Key Facts
- Patient-specific prescription required for each preparation
- State pharmacy board oversight (not FDA registration)
- USP 795 / 797 / 800 compliance standards
- Generally limited to intrastate distribution
- Cannot supply bulk office-use inventory without prescriptions
- Best for: customized patient-specific formulations
503B Outsourcing Facilities
Section 503B created a new category of compounding entity — the outsourcing facility — that voluntarily registers with the FDA and operates under Current Good Manufacturing Practice (cGMP) standards comparable to those applied to commercial pharmaceutical manufacturers. This registration enables 503B facilities to produce compounded medications in large batches without individual patient prescriptions and to ship across state lines.
For clinics, 503B is the critical pathway for office-use inventory. A clinic can order compounded peptides, injectable nutrients, or biologics from a 503B facility, hold them as clinic stock, and administer them to patients without needing a patient-specific prescription for each vial. This model is what makes high-volume regenerative medicine practices operationally feasible.
503B facilities are subject to regular FDA inspections, must comply with 21 CFR Parts 210 and 211 (cGMP regulations), and must submit adverse event reports. Their FDA registration status is publicly searchable, and their inspection records are available through FDA's database. This level of federal oversight provides a higher degree of quality assurance than state-regulated 503A pharmacies — which is why sourcing from a verified 503B facility is the recommended approach for clinic inventory.
503B — Key Facts
- No individual patient prescription required for clinic supply
- FDA registration required — voluntary but enables bulk production
- cGMP manufacturing standards (21 CFR 210/211)
- Regular FDA inspections
- Interstate shipping permitted nationwide
- Can supply clinic inventory for office use
- Best for: high-volume clinic sourcing and inventory
503A vs 503B — Side-by-Side Comparison
Key regulatory differences at a glance.
| Attribute | 503A Pharmacy | 503B Outsourcing Facility |
|---|---|---|
| Regulatory Oversight | State pharmacy board | FDA (federal) |
| Prescription Required | Yes — patient-specific | No — office use supply |
| Batch Size | Small — patient-specific | Large — bulk manufacturing |
| Manufacturing Standard | USP 795 / 797 / 800 | cGMP (21 CFR Parts 210/211) |
| FDA Registration | Not required | Required — voluntary registration |
| Interstate Shipping | Generally limited | Permitted nationwide |
| FDA Inspections | State board inspections | Regular FDA inspections |
| Clinic Inventory | Generally not permitted | Permitted for office use |
| Best For | Patient-specific formulations | Clinic stock, high-volume use |
What Documentation to Require from Your Supplier
Whether sourcing from a 503A or 503B facility, your clinic should always require the following documentation before placing orders. This protects your practice, your patients, and your compliance standing.
503B — Required Documents
- FDA registration number (verify at fda.gov)
- cGMP compliance documentation
- Certificate of Analysis (COA) per lot
- Lot number and expiration date
- Sterility test results
- Potency and purity test results
503A — Required Documents
- State pharmacy license (active, current state)
- USP 797 compliance documentation
- Certificate of Analysis (COA)
- Lot number and expiration date
- Valid prescription documentation process
- Beyond-use dating (BUD) data
How ExaVeyra Sciences Handles 503A/503B Sourcing
ExaVeyra Sciences partners with both FDA-registered 503A and 503B facilities to supply licensed clinics with compounded peptides, small molecules, and regenerative compounds. Every supplier in our network is vetted for registration status, manufacturing documentation, and COA quality before we onboard them.
Our sourcing process is reviewed by our founder — an M.Sc. organic chemist with a background in analytical chemistry and nucleotide process chemistry. We evaluate not just whether a supplier has a COA, but whether the analytical methodology behind that COA is sound — HPLC purity data, mass spectrometric identity confirmation, endotoxin testing, and stability data are all part of our evaluation framework.
For wholesale partners, we provide lot numbers and COA documentation with every order and can advise on which sourcing pathway — 503A or 503B — is most appropriate for your practice's protocols and state regulations.
503A & 503B FAQ
- What is the main difference between 503A and 503B compounding?
- 503A pharmacies prepare patient-specific compounded medications based on individual prescriptions under state pharmacy board oversight. 503B outsourcing facilities manufacture medications in bulk under FDA cGMP standards, can ship interstate without individual prescriptions, and supply clinics with office-use products. The key practical difference: 503B products do not require a patient-specific prescription and can be held as clinic inventory.
- Can a clinic order compounded peptides without a patient prescription?
- Through a 503B outsourcing facility, yes — 503B products can be supplied to clinics for office use without individual patient prescriptions. Through a 503A pharmacy, a patient-specific prescription is required. Many clinics use 503B sourcing for office-use inventory and 503A for patient-specific compounded formulations.
- What is a 503B outsourcing facility?
- A 503B outsourcing facility is an FDA-registered manufacturer that voluntarily registers with the FDA and produces compounded medications in bulk under Current Good Manufacturing Practice (cGMP) standards. They undergo FDA inspections, can produce medications without individual prescriptions, and may ship across state lines. They are subject to stricter oversight than 503A pharmacies.
- What is a 503A compounding pharmacy?
- A 503A pharmacy prepares compounded medications for individual patients based on valid prescriptions from licensed practitioners. They operate under state pharmacy board oversight and follow USP standards (USP 795, 797, 800). They cannot produce large batches for distribution without prescriptions and are generally limited to intrastate distribution.
- What documentation should I require from a 503A/503B supplier?
- For 503B products: FDA registration number, cGMP compliance documentation, certificates of analysis (COA) for each lot, lot numbers, expiration dates, and sterility test results. For 503A products: pharmacy license, USP compliance documentation, COA, and prescription handling procedures. Always verify FDA registration status at fda.gov before ordering.
- Does ExaVeyra Sciences source from 503A or 503B facilities?
- ExaVeyra partners with both FDA-registered 503A and 503B facilities depending on the product category and client need. All products are sourced with full documentation including lot numbers and COA available on request. Our founder — an M.Sc. organic chemist — reviews supplier documentation and manufacturing methodology before any product enters our catalog.
- Are exosomes regulated under 503A/503B?
- Exosomes occupy a complex regulatory space. MSC-derived exosomes are generally regulated as biological products under FDA oversight rather than as compounded drugs. The 503A/503B framework applies primarily to compounded drug products. Clinics should ensure exosome suppliers provide cGMP manufacturing documentation and COA regardless of the regulatory pathway.
- What is USP 797 and does it apply to my clinic?
- USP 797 is the United States Pharmacopeia standard for sterile compounding. It governs the preparation of sterile compounded medications including injectable formulations. If your clinic prepares or handles sterile compounded products, USP 797 compliance requirements apply. If you source pre-prepared sterile products from a 503B facility, the facility bears the USP 797 responsibility, not your clinic.
Related Resources
Exosome Sourcing Guide
How to evaluate exosome suppliers — particle count, characterization, and COA standards.
Read →Partner With Us
Apply for NPI-verified wholesale access to our 503A/503B-compliant catalog.
Read →The GLP-1 Story & 503A/503B
Why this regulatory distinction made national news — the shortage, the compounding surge, and the February 2025 regulatory shift.
Read →About Our Chemist Founder
Learn about the analytical chemistry background behind ExaVeyra's sourcing standards.
Read →Ready to Source Compliantly?
ExaVeyra Sciences supplies licensed clinics with 503A/503B-compliant peptides, biologics, and regenerative compounds. NPI-verified wholesale access, full COA documentation, and a chemist-reviewed supply chain.